TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require this therapy are being treated with anticoagulants (AC).

Anticoagulación y TAVI

Even though the current guidelines suggest interrupting anticoagulation to reduce bleeding risk, the available evidence has not yet fully elucidated this recommendation. 

This analysis of POPular PAUSE TAVI, included 858 patients treated with anticoagulants undergoing TAVR. 431 (50.2%) of these patients continued with AC (AC+), while the rest stopped AC and continued after procedure, according to treating physician criteria (AC-). 

The primary outcome was a composite of cardiovascular death, stroke, infarction, vascular complications or major bleeding within 30 days after procedure. 

Baseline group characteristics were similar: mean age 81, one third women, 3.8 STS Score, atrial fibrillation in 96% of cases, 4.5 CHA2DS2-VASc Score, 78% were hypertensive, 30% diabetic, 33% had a history of CABG, 15% had infarction history, 11% stroke, 10% TIA, 13% COPD, there was kidney function deterioration in 50% and prior TAVR in 7%.

Read also: RODIN-CUT: Successive Cutting Balloon Technique in Calcified Lesions.

There were no differences in primary end point, with 16.5% incidence in AC+ patients vs 14.8% in AC- (risk difference: 1.7 percentual points, CI 95%: −3.1 to 6.6; P = 0.18 for non-inferiority). Neither were there differences in cardiovascular mortality, all cause stroke, infarction, major bleeding or major vascular complications. 

Conclusion

In TAVR patients, periprocedural anticoagulation was shown non-inferior vs. AC interruption as regards the incidence of the combined end point of cardiovascular death, stroke, infarction, major vascular complications and major bleeding at 30 days. 

Original Title: Continuation versus Interruption of Oral Anticoagulation during TAVI. POPular PAUSE TAVI Trial.

Reference: D.J. van Ginkel, et al. N Engl J Med 2025;392:438-49. DOI: 10.1056/NEJMoa2407794.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...

New Balloon-Expandable Aortic Valve: 30-Day Outcomes in Patients with Small Aortic Annulus

As transcatheter aortic valve implantation (TAVI) continues to expand toward younger patients with longer life expectancy, factors such as valve hemodynamic performance, durability, and...

TAVI in small aortic annulus: self-expanding or balloon-expandable valve in the long term?

Patients with a small aortic annulus (a predominantly female population with a higher risk of prosthesis–patient mismatch) represent a particularly challenging subgroup within TAVI....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...